Clinical Trial Update: Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating intracerebroventricular administration of autologous CD19 CAR T cells for central nervous system lymphoma; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• CD19-CAR T cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) (CD19 CAR T cells engineered with CD28-CD3zeta signaling and EGFRt safety switch in naive/memory T lymphocytes)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Central Nervous System Lymphoma | Phase 1 | Status: RECRUITING